An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines durings the world's most influential meeting on HIV research and its ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Lenacapavir, a long-acting HIV capsid inhibitor that could potentially be given every six months, continues to show good viral suppression, both in people starting antiretroviral therapy for the first ...

Subcutaneous lenacapavir in combination with an optimized background regimen led to sustained virologic suppression in 81% of heavily treated people with HIV at week 26, data from an ongoing phase ...

Lenacapavir binds to the conical capsid that encapsulates the HIV viral genome. If successful in larger phase 3 trials, it would be the first capsid inhibitor in HIV to come to market.